23andMe

23andMe is laying off 40 per cent of its workforce, or more than 200 employees, and discontinuing its therapeutics…
Read More...

‘Barron’s Roundtable’ panelists discuss the latest headlines around 23andMe and share top stock picks. Genetics…
Read More...